NTRK1 and breast cancer: Relief of feedback to receptor tyrosine kinases has been increasingly demonstrated to be a potential resistance mechanism for inhibitors of the PI3K signalling pathway and in breast cancer this frequently occurs through increased expression and phosphorylation of the HER family of receptors, particularly HER2 and HER3 (16,24–26).